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LARC -  методи також високорентабельні, на 
відміну від КОК і презервативів. Найбільш рента­
бельним являється використання імплантатів. Імп­
лантат являється більш економічно ефективним, 
ніж КОК або ін’єкції прогестерону, а також явля­
ється більш економічно ефективним методом, ніж 
Си -  ВМС, але додаткові відношення економічної 
ефективності з часом значно зменшуються. Імп­
лантат являється економічно більш ефективним, 
ніж LNG -  ВМС, до 3 років використання.
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DOES OVARIAN AUTOIMMUNITY PLAY A ROLE 
IN THE PATHPHYSIOLOGY OF PREMATURE OVARIAN INSUFFICIENCY
The literature review is dedicated to the current state of usage antiovarian antibodies at premature ovarian failure. It 
has been analyzed literature sources in which there are indicated role of autoimmunity in the pathophysiology of premature 
ovarian insufficiency.
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Огляд літератури присвячено сучасному стану питання використання антиоваріальних антитіл при передчасній 
оваріальній недостатності. Проаналізовано літературні джерела, в яких наведено роль аутоімунних процесів в пе­
редчасній оваріальній недостатності.
Ключові слова: оваріальна недостатність, оваріальний аутоімунний процес.
Обзор литературы посвящен современному состоянию вопроса использования антиовариальных антител при 
преждевременной овариальной недостаточности. Проанализированы литературные источники, в которых показана 
роль аутоиммунных процессов в преждевременной овариальной недостаточности.
Ключевые слова: овариальная недостаточность, овариальный аутоиммунный процесс.
Premature ovarian failure (POF) is a term usu­
ally used to describe women younger than 40 years 
of age who present with amenorrhea. Diagnosis 
of POF is on the basis of follicle stimulating hor­
mone level in the menopausal range associated with 
amenorrhea before the age of 40. Women diagnosed 
with the POF suffered from anovulation and hy- 
poestrogenism and presented with primary or sec­
ondary amenorrhea, infertility, sex steroid deficien­
cy, and elevated gonadotrophins [1, p. 245] POF is 
the causative factor in 10-28% of women present­
ing with amenorrhea and in 4-18% with secondary 
amenorrhea [2, p. 236; 3, p. 45]. The course of POF 
is poorly defined [4, p. 112]. Perhaps 50% of sponta­
neously affected woman have the evidence of follic­
ular activity and probably 25% ovulate even before
18
Медичний форум
the diagnosis is established. Some of these women 
even conceive. It is increasingly felt that it may be 
appropriate to refer to them as patients with «prima­
ry ovarian insufficiency.» The term primary ovarian 
insufficiency (POI) originally suggested by Albright 
appropriately describes a continuation of impaired 
ovarian function and is also less stigmatizing than 
the terms used previously [5, p. 38]. Two mecha­
nisms are probably involved in POI, namely follicle 
dysfunction and follicle depletion [6, p. 253]. The 
existing follicles in the ovary, in follicle dysfunc­
tion, do not function normally due to some patho­
logical process such as for e.g. FSH-receptor mu­
tation [7, p. 86]. On the other hand, in women with 
follicle depletion there are no primordial follicles 
probably due to inadequate initial pool of primor­
dial follicles or destruction of follicles due to toxins 
or autoimmune mechanisms [5, p.39]. The primary 
goal of the scientists working in this area should be 
to focus on the etiology of POI [8, p. 99] Some of 
the causes can lead to complete absence of oocytes, 
and others can lead to inability of follicles to mature 
or to disordered folliculogenesis. The causes could 
be chromosomal, genetic, autoimmune, metabolic 
(galactosemia), infection (mumps), and iatrogen­
ic [9, p. 123]. Among the several mechanisms that 
account for the pathogenesis of spontaneous POI, 
genetic and autoimmune mechanisms play a major 
role. X-chromosome abnormalities have been sys­
tematically reviewed by Persani et al [10, p. 96]/ 
Normal ovarian function requires two functioning 
X chromosomes. In the Turner Syndrome, there is a 
complete loss of the second chromosome resulting 
in the most severe and irreversible POI often clini­
cally evident prior to menarche [11, p. 176]. Preva­
lence of other genetic defects causing POI has been 
difficult to determine. Gene for blepharophimosis/ 
ptosis/POI syndrome has been recently reported but 
has not been seen commonly in patients with POI. 
Of the various knock out mice models created with 
deficient ovarian function, the most interesting one 
is a heterozygous FSH receptor knock out mouse, 
which has exhibited a reduced follicle reserve and 
early ovarian depletion [11, p.29]. In this review, 
we will focus on the role of autoimmunity in the 
pathophysiology of POI. The human ovary can 
be a target for an autoimmune attack under vari­
ous circumstances. Clinically, the ensuing ovarian 
dysfunction often results in premature ovarian in­
sufficiency characterized by amenorrhea lasting 
4-6 months and is classically defined as secondary 
amenorrhea accompanied by a hypergonadotropic- 
hypoestrogenic condition before the age of 40 years 
[12, p. 49]. It has long been recognized that POI 
could be associated with nearly all organ-specific 
and non-organ-specific autoimmune diseases, and
its association with the endocrine glands such as the 
thyroid, pancreas, and adrenal glands has been re­
ported [13, p. 68]. Vallotton and Forbes [14, p. 66] 
were the first to describe the presence of antibodies 
to rabbit ova cytoplasm using sera from POI pa­
tients. Autoimmune POI (AI-POI) is characterized 
by organ-specific targeting of the immune response 
accompanied by tissue destruction, which can have 
widespread systemic complications in severe cas­
es. The disease affects 1% of the general popula­
tion [15, p. 78]). There could be several reasons for 
the differences among the study results. First, study 
design elements, such as antibody test format and 
antigen preparation and criteria for study and com­
parison groups differ. Second, there may be sever­
al antigenic targets, and often only one may have 
been assessed. Moncayo et al [19, p. 58]/ developed 
an ELISA using microsomes from bovine corpo­
ra lutea as the antigen. Luborsky et al. [17, p. 39] 
developed an ELISA kit using total human ovary/ 
oocytes as antigen and showed that sera from 71% 
of women with POF in their study had antibodies 
either to whole ovary or to oocytes. Wheatcroft et al 
[20, p. 66]/ reported an incidence ranging from 24% 
to 60%, depending on the source of ovarian antigen. 
This difference was attributed to a cyclical variation 
in antigenic proteins. A review published in 2006 re­
ported that autoantigens and specific autoantibodies 
for the diagnosis of autoimmune POF remain to be 
determined [23, p. 245].
Antibodies to several potential ovarian antigens 
were proposed as markers of ovarian autoimmunity. 
They were LH receptor, [24, p. 58] FSH receptor 
[25, p. 36; 26, p. 56] zona pellucida (ZP), [27, p. 56] 
and several other antigens [22, p. 56].
In the context of POI, a false-positive report in­
dicating autoimmunity as the mechanism of sponta­
neous POI could put young women at risk of inap­
propriate therapy, with serious consequences such 
as development of osteonecrosis due to glucocorti­
coid therapy [33, p. 48]. As the clinicians' diagno­
sis will be based exclusively and extensively on the 
detection of the presence or absence of ovarian anti­
bodies, it is crucial that the diagnosis is a foolproof. 
An early and specific diagnosis of POI (especially 
AI-POI) is now possible with the test developed by 
us [30, p. 49]. This will be extremely useful for di­
agnosis as well as therapy for these women. The test 
enabled specific detection of antiovarian antibodies 
(AOAs) along with the identification of different 
molecular and cellular antigenic targets in the ova­
ry [16, p.56]. This is important because [1, p. 133] 
it will help identify antigenic targets that will lead 
to the development of reagents to screen for AOAs 
that could serve as an analytical tool to detect the 
disease and consequently design a drug regimen for
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treatment [2, p. 49]. Results from laboratory clear­
ly showed that there are specific AOAs in the sera 
of patients with POF. In patients who had failed 
at IVF-ET, AOA positivity as detected by western 
blotting and immunohistochemistry (IHC), could be 
involved in POI [29, p. 29]. Reactivity of AOAs to 
ovarian cell types has been shown by indirect immu- 
noflourescence (IIF) [19, p. 44]. Reactivity of POF 
patient sera with ZP has been reported [27, p. 63; 
11, p. 187]. It was suggested that Zp could be an im­
portant ovarian antigen. However, our data clearly 
indicated that, besides ZP, several proteins from oth­
er cellular targets such as oocytes, corpus luteum, 
theca, and granulosa cells are also involved in ovar­
ian autoimmunity, and therefore, there cannot be a 
diagnostic test on the basis of one single biomarker 
[28, p. 68]. It is possible that inpatients showing re­
activity to oocytes and granulosa cells the antibod­
ies may damage the bidirectional communication 
which is necessary for proper folliculogenesis as 
reported recently. [21, p. 94]. A specific noninvasive 
test is particularly important for a reliable diagnosis 
of an autoimmune etiology and is essential to detect 
concomitant or future associated disorders, as well 
as to select the patients in whom immune-modulat­
ing therapy may restore, at least temporarily, ovari­
an function and fertility. Glucocorticoid therapy has 
been suggested to restore ovarian function [13, p. 66]. 
A prospective, randomized controlled study of al­
ternate prednisone therapy for AI-POF was taken 
up at clinical center of the National Institutes of 
Health. However, lack of a noninvasive diagnostic 
serum marker necessitated histological confirma­
tion of the disease using biopsy before prednisone 
administration. Repeated IVF attempts are likely 
to induce production of AOAs because of repeat­
ed hormonal stimulation [19, p. 45] and repeated 
microtrauma during oocyte retrieval [24, p. 88]. It 
has been shown by these researchers that these an­
tibodies could affect egg development and embryo 
development and could be responsible for implanta­
tion failures. There are the reports showing higher 
prevalence of these antibodies in patients with IVF 
failures than those with IVF success [25, p. 87]. It
has also been stressed that follicular aspiration may 
not be the cause for antiovarian autoimmunization 
[26, p. 69]. Moreover, in some cases, AOAs appear 
after follicular aspiration, whereas in other cases, pre­
existing AOA levels increase with the number of IVF 
attempts [27, p. 69] Therefore, testing for the presence 
of AOAs in women before initiation into the IVF-ET 
program should be recommended because this would 
help to counsel the patients regarding the reproduc­
tive outcome with iVf . We also propose that the AOA 
test should be a part of the battery of tests included 
for infertility treatment and management. Very little 
is known about the precise nature of the ovarian an­
tigens that are recognized by the antibodies in sera. 
Antigens of oocyte, [14, p. 238] corpus luteum, [17, 
p. 69] granulosa cells, [16, p. 128] and ZP [21,p. 62] 
have been reported to act as autoantigens; however, 
their molecular identity and pathophysiologic signif­
icance remain obscure. The oocyte seems to be the 
most often targeted cell of AOA detected in cases 
of ovarian diseases as well as in women with poor 
assisted reproductive technologies (ART) outcomes 
[22, p. 89]. A thorough literature review on infertil­
ity with autoimmune involvement has indicated that 
very few proteins have been formally identified and 
characterized using sera of women with infertility 
[28, p. 146]. One report demonstrated autoantibod­
ies to a-enolase, [30, p. 66] and several reports have 
shown the presence of circulating antibodies directed 
toward different ovarian structures [16, p. 49; 17, p. 57; 
22, p. 86] Identification and systematic characteriza­
tion of target antigens are the prerequisites for elu­
cidation of the underlying immunologic mechanisms 
and also for devising better approaches for the diag­
nosis and treatment of POI leading to infertility [36, 
p. 89]. Once their identity has been established, they 
could be used for simple, noninvasive diagnostic tests 
to screen large populations of women with infertility 
or repeated implantation failures as well as to screen 
patients before and after enrollment in an IVF-ET 
program.
Although a number of tests have been developed 
to detect these antibodies, neither their specificity 
nor their diagnostic relevance has been established.
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